Products
Ecleralimab Biosimilar Monoclonal Antibody (TSLP) for Research
Pre-Made Ecleralimab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-662-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Ecleralimab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody |
| INN Name | Ecleralimab |
| Target | TSLP |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2021 |
| Year Recommended | na |
| Companies | Novartis |
| Conditions Approved | na |
| Conditions Active | Asthma |
| Conditions Discontinued | na |
| Development Tech | na |
About target - TSLP
1. Protein Thymic stromal lymphopoietin
2. Gene TSLP
3. Organism Homo sapiens (Human)
Function
Isoform 2:
Cytokine that induces the release of T-cell-attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c+ dendritic cells. Can induce allergic inflammation by directly activating mast cells.
Isoform 2:
May act as an antimicrobial peptide in the oral cavity and on the skin.
Miscellaneous
Is not capable of signal transduction by itself, but operates through the adapter protein HCST (PubMed:10426994 and PubMed:15894612). Some families of ligands for human and mouse KLRK1 receptors have been characterized being very similar in structure and highly likely to be orthologs. In humans, an additional distinct subfamily of ligands (MICA and MICB) differs structurally, having an extra MHC alpha 3-like domain (PubMed:23298206).
